Helen Giza: Vorstandschefin von FMC geht abrupt– Aktie fällt deutlich
Nach knapp vier Jahren an der Spitze des Dialysekonzerns geht Helen Giza vorzeitig. Die Trennung verlief laut Insidern nicht einvernehmlich. Die Aktie gibt kräftig nach.
Munich: Fresenius Medical Care (FMC) abruptly changed its leadership when Helen Giza, the company's Chief Executive Officer, left the organization at the end of the week, the company announced on Wednesday. Giza had been in the position for nearly four years and previously served as the finance chief for three years. FMC's shares dropped by more than seven percent following the news.
According to Handelsblatt information, the move was not mutually agreed upon, as the board and supervisory board unanimously decided to part ways with Giza. While Giza managed the cost side effectively, she lacked a compelling strategy for FMC's continued growth, insiders revealed. The strategy presented at the capital market day did not "ignite," indicating further disappointment.
After the capital market day, the share price fell by 16 percent. The supervisory board acknowledged that they should have acted after the second quarter. Under Giza's leadership, the company faced stagnant treatment numbers in the US market. In recent years, FMC's US competitor, Davita, grew significantly faster and surpassed FMC. This news disappointed investors.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
